Biomarkers for acute kidney injury: Where are we today? Where should we go?

Clinical Chemistry

Volumn 60, Issue 2, 2014, Pages 294-300

  Lieske, John C ^a   Chawla, Lakhmir ^b   Kashani, Kianoush ^a   Kellum, John A ^c   Koyner, Jay L ^d   Mehta, Ravindra L ^e  

^a MAYO CLINIC   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; INSULIN GROWTH FACTOR BINDING PROTEIN 7; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AWARENESS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS; CONVALESCENCE; COST; CREATININE BLOOD LEVEL; DIALYSIS; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; G1 PHASE CELL CYCLE CHECKPOINT; KIDNEY PERFUSION; MEDICAL RESEARCH; NOTE; PREDICTIVE VALUE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; S PHASE CELL CYCLE CHECKPOINT; URINE VOLUME; ACUTE KIDNEY INJURY; BLOOD; HUMAN; URINE;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CREATININE; EARLY DIAGNOSIS; HUMANS; PROGNOSIS;

EID: 84893493984     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.201988     Document Type: Note

References (0)